Dorzolamid Hexal: Uses, Dosage & Side Effects

What Is Dorzolamid Hexal and What Is It Used For?

Dorzolamid Hexal contains dorzolamide hydrochloride, a potent and selective inhibitor of human carbonic anhydrase isoenzyme II (CA-II). Carbonic anhydrase is an enzyme found throughout the body, but its role in the ciliary processes of the eye is particularly relevant for glaucoma treatment. In the eye, CA-II catalyzes the reversible hydration of carbon dioxide to form bicarbonate ions and protons. This reaction is essential for the active secretion of aqueous humor – the clear fluid that fills the anterior and posterior chambers of the eye, nourishing the lens and cornea while maintaining the eye’s structural integrity and shape.

By inhibiting CA-II in the ciliary epithelium, dorzolamide slows the formation of bicarbonate ions, which in turn reduces the transport of sodium ions and water into the posterior chamber. Clinical studies have demonstrated that topical dorzolamide 2% decreases aqueous humor production by approximately 40–50% compared with baseline secretion rates. This reduction translates into a clinically meaningful lowering of intraocular pressure (IOP) – typically in the range of 3–5 mmHg when used as monotherapy. The onset of IOP-lowering effect occurs within 1–2 hours of instillation, with peak effect at approximately 2–3 hours.

Elevated IOP remains the most important modifiable risk factor for the development and progression of glaucoma, a group of optic neuropathies characterized by progressive damage to the optic nerve head and loss of retinal ganglion cells. Glaucoma is the leading cause of irreversible blindness worldwide, affecting an estimated 80 million people globally. Open-angle glaucoma, the most common form, typically develops gradually and painlessly, with peripheral vision loss that can progress to complete blindness if left untreated. Ocular hypertension refers to consistently elevated IOP without detectable optic nerve damage or visual field loss – a condition that significantly increases the risk of developing glaucoma over time.

Dorzolamid Hexal is approved for two primary indications. First, it may be used as monotherapy to lower IOP in patients with open-angle glaucoma or ocular hypertension for whom topical beta-adrenergic receptor blocking agents (beta-blockers) are not appropriate. Beta-blockers such as timolol are traditionally considered first-line therapy for glaucoma, but they are contraindicated in patients with certain cardiovascular conditions (such as bradycardia, heart block, or decompensated heart failure), respiratory conditions (such as asthma or severe chronic obstructive pulmonary disease), or other medical situations where systemic beta-blockade would be harmful. Second, Dorzolamid Hexal is used as adjunctive therapy in combination with topical beta-blockers when a single agent alone does not achieve sufficient IOP reduction.

The European Glaucoma Society (EGS) guidelines and the American Academy of Ophthalmology (AAO) Preferred Practice Patterns recognize topical carbonic anhydrase inhibitors as an important class of IOP-lowering medications, recommended either as first-line alternatives to beta-blockers or as second-line add-on therapy. Dorzolamide is included on the World Health Organization (WHO) Model List of Essential Medicines, underscoring its global importance in the management of glaucoma.

What Should You Know Before Using Dorzolamid Hexal?

Contraindications

Certain conditions make the use of Dorzolamid Hexal inappropriate or potentially dangerous. Understanding these contraindications is essential before beginning treatment.

• Hypersensitivity: Do not use Dorzolamid Hexal if you are allergic to dorzolamide hydrochloride or any of the excipients in the formulation (hydroxyethyl cellulose, mannitol, sodium citrate dihydrate, sodium hydroxide, benzalkonium chloride, and water for injections). Dorzolamide is a sulfonamide derivative, and although topical ophthalmic use results in much lower systemic exposure than oral sulfonamides, cross-sensitivity reactions have been reported. Patients with a known history of hypersensitivity to sulfonamides (e.g., sulfamethoxazole, furosemide, acetazolamide) should discuss this with their doctor.
• Severe renal impairment: Dorzolamide and its metabolite N-desmethyl dorzolamide are excreted primarily by the kidneys. In patients with severe renal impairment (creatinine clearance below 30 ml/min), drug accumulation may occur, increasing the risk of systemic adverse effects. Dorzolamid Hexal is contraindicated in these patients.
• Hyperchloremic acidosis: Because dorzolamide inhibits carbonic anhydrase, its use in patients with pre-existing hyperchloremic acidosis could worsen the acid-base imbalance. The medication is contraindicated in this condition.

Warnings and Precautions

Before and during treatment with Dorzolamid Hexal, consider the following precautions:

• Corneal endothelium: Topical carbonic anhydrase inhibitors have been associated with corneal edema and irreversible corneal decompensation in patients with pre-existing low endothelial cell counts. Patients who have had corneal surgery or who have corneal endothelial disease (such as Fuchs’ endothelial dystrophy) are at higher risk. Your ophthalmologist may monitor corneal thickness and endothelial cell counts if you have known corneal vulnerabilities.
• Kidney stones: Cases of nephrolithiasis (kidney stones) have been reported during treatment with dorzolamide. While the risk is low with topical ophthalmic use, patients with a history of kidney stones should be monitored.
• Hepatic impairment: Dorzolamide has not been studied in patients with hepatic impairment. Since metabolism occurs in part through the liver, use caution in patients with significant liver disease.
• Acute angle-closure glaucoma: The IOP-lowering effect of dorzolamide has not been evaluated in patients with acute angle-closure glaucoma. Acute angle-closure is a medical emergency requiring immediate treatment; dorzolamide alone is not appropriate as initial management.
• Contact lenses: Dorzolamid Hexal contains the preservative benzalkonium chloride, which can be absorbed by soft contact lenses, causing irritation and discoloration. Remove contact lenses before instilling the eye drops and wait at least 15 minutes before reinserting them. Benzalkonium chloride can also cause punctate keratopathy and/or toxic ulcerative keratopathy with prolonged use.
• Concomitant oral carbonic anhydrase inhibitors: Combining topical dorzolamide with oral carbonic anhydrase inhibitors (such as acetazolamide) is not recommended. The combination increases systemic inhibition of carbonic anhydrase without providing additional IOP-lowering benefit, while significantly increasing the risk of systemic adverse effects including metabolic acidosis, kidney stones, and electrolyte disturbances.

Pregnancy and Breastfeeding

There are no adequate and well-controlled studies of dorzolamide use in pregnant women. Animal reproduction studies with orally administered dorzolamide at doses far exceeding the ophthalmic dose have shown developmental toxicity including malformations of the vertebral bodies. While topical ophthalmic administration results in much lower systemic exposure than oral dosing, the potential risk to the fetus cannot be fully excluded. Dorzolamid Hexal should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus, and only after careful consideration by the treating physician.

It is not known whether dorzolamide is excreted in human breast milk following topical ophthalmic administration. Studies in lactating rats administered oral dorzolamide showed that the drug and its metabolite were present in milk. Given the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue breastfeeding or to discontinue the medication, taking into account the importance of the drug for the mother. Discuss the risks and benefits with your doctor.

Effects on Ability to Drive and Use Machines

Dorzolamide eye drops may cause temporary blurred vision or other visual disturbances immediately after instillation. If this occurs, do not drive or operate machinery until your vision has cleared. Patients should be aware that these transient visual effects typically resolve within a few minutes of application but should exercise caution, particularly when first starting treatment or when changing dosage.

How Does Dorzolamid Hexal Interact with Other Drugs?

Drug interactions with topical dorzolamide are relatively limited compared with oral medications, because the systemic absorption from eye drops is substantially lower. Nevertheless, several important interactions should be considered. Always inform your ophthalmologist and general practitioner about all medications you are using, including prescription drugs, over-the-counter products, and herbal supplements.

Major Interactions

• High-dose salicylates (aspirin): Although no specific interaction studies have been performed with topical dorzolamide and high-dose aspirin, the potential for interaction exists. Oral carbonic anhydrase inhibitors have been reported to alter the disposition and toxicity of high-dose salicylates, potentially leading to salicylate toxicity with symptoms including tinnitus, confusion, and metabolic disturbances. Patients taking high-dose aspirin therapy (e.g., for rheumatic conditions) should be monitored.

Minor Interactions and Considerations

• Other topical ophthalmic agents: Dorzolamid Hexal can generally be used alongside other topical glaucoma medications including beta-blockers (timolol, betaxolol), prostaglandin analogues (latanoprost, travoprost, bimatoprost), alpha-2 agonists (brimonidine), and miotics (pilocarpine). When using multiple eye drops, administer them at least 10 minutes apart to ensure proper absorption and prevent one drop from diluting or washing away the other.
• CYP enzyme interactions: In vitro studies have shown that dorzolamide primarily inhibits CYP2C9 and, to a lesser extent, CYP2C19. However, the systemic concentrations achieved after topical ophthalmic administration are far below those required for clinically meaningful enzyme inhibition. No clinically significant cytochrome P450-mediated drug interactions have been reported with topical dorzolamide.

What Is the Correct Dosage of Dorzolamid Hexal?

The dosage of Dorzolamid Hexal is determined by your ophthalmologist based on the indication, whether the medication is used alone or with other eye drops, and your individual response to treatment. The following are the standard recommended dosages based on approved prescribing information and international ophthalmology guidelines.

Adults

If you are switching from another antiglaucoma medication to Dorzolamid Hexal, your doctor may instruct you to continue the current medication for one day before starting dorzolamide, or to begin dorzolamide on the same day that the other medication is discontinued. This transition strategy depends on the specific medications involved and is determined by your ophthalmologist.

Children

Limited clinical data are available on the use of dorzolamide in pediatric patients. In general, the dosing recommendations for children and adolescents with glaucoma or ocular hypertension follow the same regimen as adults: one drop three times daily as monotherapy or one drop twice daily as adjunctive therapy. However, pediatric glaucoma management is specialized, and treatment should always be supervised by a pediatric ophthalmologist or glaucoma specialist. The safety and efficacy profile in infants and very young children has not been fully established.

Elderly

No dosage adjustment is required for elderly patients with normal renal function. Glaucoma is predominantly a disease of the elderly population, and the majority of clinical trial data for dorzolamide were obtained in older patients. Renal function should be assessed before starting treatment in elderly patients, as age-related decline in kidney function may affect the clearance of dorzolamide and its metabolites. The medication should be used with caution in patients with moderate renal impairment and is contraindicated in those with severe renal impairment.

Missed Dose

If you forget to instill a dose, apply it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. Do not instill a double dose to make up for a forgotten one. Consistent, regular use is important for maintaining steady IOP control. If you frequently forget doses, consider setting reminders or discussing your dosing schedule with your doctor to identify a more convenient regimen.

Overdose

Topical overdose with dorzolamide eye drops is unlikely to cause serious systemic effects due to the limited amount of drug in each bottle. If excessive amounts are accidentally instilled into the eye, the most likely effects are local irritation, burning, and tearing. Rinse the affected eye(s) with clean water or sterile saline solution. If the eye drops are accidentally swallowed, particularly by a child, contact a poison control center or seek medical attention. Potential systemic effects of large oral doses could include electrolyte imbalances and metabolic acidosis. Treatment is supportive, with monitoring of serum electrolytes and acid-base balance.

What Are the Side Effects of Dorzolamid Hexal?

Like all medicines, Dorzolamid Hexal can cause side effects, although not everyone experiences them. The side effects listed below are based on data from clinical trials and post-marketing surveillance. Side effects are categorized by frequency according to established conventions: very common (affects more than 1 in 10 patients), common (1 in 10 to 1 in 100), uncommon (1 in 100 to 1 in 1,000), rare (1 in 1,000 to 1 in 10,000), and not known (cannot be estimated from available data).

Most ocular side effects of dorzolamide are local, mild, and transient. The burning and stinging sensation typically diminishes within seconds to minutes after instillation and often becomes less bothersome with continued use as the eye becomes accustomed to the medication. The bitter taste is related to drainage of the solution through the nasolacrimal duct into the pharynx and can be minimized by performing punctal occlusion (pressing on the inner corner of the eye after instillation).

Systemic side effects are uncommon with topical ophthalmic dorzolamide because only a small fraction of the applied dose reaches the systemic circulation. However, because dorzolamide does accumulate in red blood cells (binding to CA-II), some degree of systemic carbonic anhydrase inhibition can occur with prolonged use. Patients should be aware of both local and systemic adverse effects and report any unusual or persistent symptoms to their healthcare provider.

How Should You Store Dorzolamid Hexal?

Proper storage of Dorzolamid Hexal is essential to maintain the sterility, stability, and efficacy of the eye drops throughout the period of use. Ophthalmic solutions are particularly sensitive to contamination because they are applied directly to the eye, an organ that is highly vulnerable to infection.

Store the unopened bottle at room temperature, not exceeding 30°C (86°F). Protect the bottle from light by keeping it in its original outer carton when not in use. Do not freeze the solution, as freezing can alter the formulation and render it unsuitable for use. Keep the bottle tightly closed when not in use to prevent contamination and evaporation.

Once the bottle has been opened, Dorzolamid Hexal should be used within 28 days. After this period, discard the bottle even if there is solution remaining. The preservative benzalkonium chloride helps to prevent microbial contamination during the in-use period, but its effectiveness diminishes over time, and repeated opening and closing of the bottle introduces a cumulative risk of contamination. Write the date of opening on the bottle or its carton to help track the 28-day window.

Keep Dorzolamid Hexal out of the sight and reach of children. Do not use the medication after the expiry date stated on the bottle and carton (marked “EXP”). The expiry date refers to the last day of the stated month. Do not dispose of medications through wastewater or household waste. Ask your pharmacist about how to dispose of medicines you no longer use, in accordance with local regulations.

What Does Dorzolamid Hexal Contain?

Understanding the full composition of Dorzolamid Hexal is important, particularly for patients with known allergies or sensitivities to specific excipients. The formulation has been designed to maintain the stability, pH, and viscosity of the solution while ensuring tolerability upon ocular application.

Active substance: Each milliliter of eye drop solution contains dorzolamide hydrochloride equivalent to 20 mg dorzolamide. The hydrochloride salt form ensures adequate water solubility for the ophthalmic solution. Each drop (approximately 30 microliters) delivers approximately 0.6 mg of dorzolamide to the eye.

Excipients:

• Hydroxyethyl cellulose: A viscosity-increasing agent that helps the solution remain on the eye surface longer, improving contact time and drug absorption.
• Mannitol: Used as a tonicity agent to ensure the solution is isotonic (has the same osmotic pressure as tears), minimizing irritation upon instillation.
• Sodium citrate dihydrate: A buffering agent that helps maintain the pH of the solution within an acceptable range for ocular comfort (approximately pH 5.6).
• Sodium hydroxide: Used for pH adjustment during manufacturing.
• Benzalkonium chloride (0.075 mg/ml): A quaternary ammonium preservative that prevents microbial contamination of the multi-dose bottle. Benzalkonium chloride can be absorbed by soft contact lenses and may cause eye irritation in some sensitive individuals. Preservative-free alternatives may be available for patients who are intolerant to benzalkonium chloride.
• Water for injections: The vehicle (solvent) for the formulation.

The solution is clear, slightly viscous, and colorless to nearly colorless. It is supplied in a plastic Drop-Tainer dispensing bottle, typically containing 5 ml of solution. The slightly acidic pH (approximately 5.6) is necessary for the stability of dorzolamide in solution and may contribute to the transient stinging sensation upon instillation.